NCH Healthcare System [ ICU] Antibiogram 2012

NCH Healthcare System [ ICU] ... 433 99 83 91 93 93 93 93 92 100 98 99 93 96 96 91 . Proteus ... NCH Healthcare System Inpatient Antibiogram 2012 ;...

1 downloads 502 Views 207KB Size
NCH Healthcare System [ ICU] Antibiogram 2012 (% Susceptible)

organism

55

96

36

80.7

Ps.aeruginosa

41 1

95.1

organism S.aureus

63

36.3

54.5

78.1

87.2 85.1

87.2

87.2

47.2

100

87.2

100

49

94.2

100

78.1

68.5

75

83.3

83.3 88.8

83.3

83.3

86.1

94.1

94.4

88.8

86.1

78

87.5

86.1

80.5

87.8

80.4

78.5

92.8

66.6

92.3

95.2

80.9

#t est

ed

am pic illin cip rof lox aci clin n da my cin da p to my cin ery th r om yci n gen tam gen icin tam icin syn str erg ep tom y y c i lev ns ofl yne oxa rgy cin line zol id mo xifl oxc in nit rof ura nti on oxa cill in rifa mp in tet rac y cl ine tig e cy cli trim ne eth /su lfa van com yci n

K.pneumoniae

1

avg .

E.coli

avg .

#t est

ed am ika cin am pic illin am p/s ulb ce f azo lin ce f ep im e ce f oxi tin ce f taz idim e ce f tria xon e cip rof lox aci n ert ap en em gen tam icin im ipe ne m lev ofl oxa cin nit rof ura nti pip on /ta zo tig e cy clin e tob ram y ci n trim eth /su lfa

data collection period Oct 2010 - Sept 2011

Enterococcus spp. 1

<30

1

38 41.2 100 23.8 95.2 95.2 83.3 61 100 17.6 95.4

38 100 49.2 49.2 36.5 65 65.5 91 95

96.8 100 100 100 14 100

100 90

results should be interpreted with caution since the number of isolates does not meet the statistically valid number of >50 isolates, recommended by CLSI Enterococcus spp. includes: E. faecium, E.faecalis and two VRE's Vancomycin Resistant Enterococci

2

Note to Physician / Pharmacist: For atypical susceptibility patterns or multiply resistant organisms, additional susceptibilities may be available. Please call the Microbiology Dept at 239-436-6591.

NCH Healthcare System ED Antibiogram 2012 Common Gram-Positive Bacterial Pathogens (% - Susceptible) Data Collected Oct 2010 – Sept 2011

Pathogens

Enterococcus spp Staph aureus Strep pneumoniae

Avg. # Test ed

136 55 * 29

A m p i c i l l i n

C e f t r i a x o n e

99 99

C l i n d a m y c i n

70

C i p r o f l o x a c I n

80 64

D a p t o m y c i n

100

E r y t h r o m y c i n

57 59

G e n t a m i c i n

100

G e n t a m i c i n

83

S y n e r g y

L e v o f l o x a c i n

L i n e z o l i d

82 64 100

100 100

N i t r o f u r a n t o i n

99 95

O x a c i l l i n

64

P e n i c i l l i n

68

R i f a m p i n

97

T e t r a c y c l i n e

18 88 76

T i g e c y c l i n e

100 100

T r i m e t h / S u l f a

100

V a n c o m y c i n

100 100 100

Antibiotics which are not reported are either inactive against the organism, or the resistance rate is > 50%, or not a drug of choice. should be viewed with caution since the number of isolates does not meet the statistically valid number of > 50 isolates recommended by the CLSI. • Gentamicin may provide synergistic activity when used in combination therapy with a penicillin (ampicillin) or vancomycin for deep-seeded enterococcal infections. • Rifampin should not be used as a single agent for treatment but may be effectively used as combination therapy with vancomycin, trimethoprim/sulfamethoxazole, or doxycycline or minocycle • Strep pneumoniae: Includes Data from ED patients and Inpatient sterile sites (Blood, CSF, Fluid, Lung Tissue)

# Results

Note to Physician / Pharmacist: For atypical susceptibility patterns or multiply resistant organisms, additional susceptibilities may be available. Please call the Microbiology Dept at 239-436-6591.

NCH Healthcare System ED Urine Antibiogram 2012 Common Gram-Negative Bacterial Pathogens (% - Susceptible) Data Collected Oct 2010 – Sept 2011

Pathogens

Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli ESBL Escherichia coli Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens Stenotrophomo nas maltophilia

Avg. # Tested

A m i k a c i n

A m p / S u l b a c t a m

A m p i c i l l i n

C e f a z o l i n

C e f e p i m e

C e f o x i t i n

C e f t r i a x o n e

C i p r o f l o x a c i n

E r t a p e n e m

G e n t a m i c i n

I m i p e n e m

L e v o f l o x a c i n

100

100

100

100

100

100

100

N i t r o f u r a n t o i n

P i p / T a z o b a c t a m

T o b r a m y c i n

T r i m e t h / S u l f a

100

100

100

86

*21

100

100

*29

100

100

96

96

90

100

100

100

90

14

96

100

100

* 17

100

100

76

76

100

100

100

100

100

33

93

100

88

1506

100

95

95

81

100

92

100

81

95

95

91

73

67

100

12

100

73

100

12

92

50

53

59

245

100

93

100

97

99

98

90

145

100

92

92

98

97

96

59

98

88

100

100

* 23

68

53

87

96

0

C e f t a z i d i m e

93

13

76

96

98

98

98

98

97

100

99

94

100

99

100

100

92

100

94

95 23

100

77 96

91

100

26

82

93

71

96

97

100

100

91

91

100

* 30

100 90

■ Antibiotics which are not reported are either inactive against the organism, or , the resistance rate is > 50%, or, not a drug of choice. * Results should be viewed with caution since the number of isolates does not meet the statistically valid number of > 50 isolates recommended by the CLSI.

Note to Physician / Pharmacist: For atypical susceptibility patterns or multiply resistant organisms, additional susceptibilities may be available. Please call the Microbiology Dept at 239-436-6591.

NCH Healthcare System Inpatient Antibiogram 2012 Common Gram-Negative Bacterial Pathogens (% - Susceptible) Inpatient Data Collected Oct 2010 – Sept 2011

Pathogens

Avg. # Tested

A m i k a c i n

A m p / S u l b a c t a m

A m p i c i l l i n

C e f a z o l i n

C e f e p i m e

Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli

33

100

100

47

100

74

98

1415

100

ESBL Escherichia coli Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens Stenotrophomo nas maltophilia

138

97

433

99

83

204

99

93

363

97

85

* 23

100

100

60

47

82

C e f o x i t i n

C e f t r i a x o n e

E r t a p e n e m

G e n t a m i c i n

I m i p e n e m

L e v o f l o x a c i n

N i t r o f u r a n t o i n

P i p / T a z o b a c t a m

T o b r a m y c i n

T r i m e t h / S u l f a

85

79

100

89

100

79

87

86

94

79

100

91

91

96

100

98

100

94

7

84

100

98

97

81

82

85

98

89

100

85

33

80

90

88

89

90

64

100

89

100

64

94

94

86

71

3

100

73

100

3

89

77

43

54

99

93

96

96

91

77

98

95

78

88

4

74

C i p r o f l o x a c i n

82

90

0

C e f t a z i d i m e

91

93

93

93

93

92

100

98

89

95

94

95

95

76

100

93

93 23

100

77 96

91

100

87

93

71

89

97

100

100

91

91

100

* 30

100 90

■ Antibiotics which are not reported are either inactive against the organism, or , the resistance rate is > 50%, or, not a drug of choice. * Results should be viewed with caution since the number of isolates does not meet the statistically valid number of > 50 isolates recommended by the CLSI.

Note to Physician / Pharmacist: For atypical susceptibility patterns or multiply resistant organisms, additional susceptibilities may be available. Please call the Microbiology Dept at 239-436-6591.

NCH Healthcare System Inpatient Antibiogram 2012 Common Gram-Positive Bacterial Pathogens (% - Susceptible) Inpatient Data Collected Oct 2010 – Sept 2011

Pathogens

Enterococcus faecium Enterococcus spp Staph aureus Staph epidermidis Strep pneumoniae

Avg. # Test ed

41 230 688 159 * 29

A m p i c i l l i n

C e f t r i a x o n e

96 99

C l i n d a m y c i n

56 55

C i p r o f l o x a c I n

79 45 30

D a p t o m y c i n

100 100

E r y t h r o m y c i n

58 32 59

G e n t a m i c i n

G e n t a m i c i n S y n e r g y

83 69

100 76

L e v o f l o x a c i n

L i n e z o l i d

10 72 45 30 100

100 99 100 100

N i t r o f u r a n t o i n

94 99 99

O x a c i l l i n

45 26

P e n i c i l l i n

68

R i f a m p i n

97 95

T e t r a c y c l i n e

24 17 94 84 76

T i g e c y c l i n e

100 100 100 100

T r i m e t h / S u l f a

98

V a n c o m y c i n

17 100 100 100 100

Antibiotics which are not reported are either inactive against the organism, or the resistance rate is > 50%, or not a drug of choice. # Results should be viewed with caution since the number of isolates does not meet the statistically valid number of > 50 isolates recommended by the CLSI. • Gentamicin may provide synergistic activity when used in combination therapy with a penicillin (ampicillin) or vancomycin for deep-seeded enterococcal infections. • Rifampin should not be used as a single agent for treatment but may be effectively used as combination therapy with vancomycin, trimethoprim/sulfamethoxazole, or doxycycline or minocycle • Strep pneumoniae: Includes Data from ED patients and Inpatient sterile sites (Blood, CSF, Fluid, Lung Tissue)

Note to Physician / Pharmacist: For atypical susceptibility patterns or multiply resistant organisms, additional susceptibilities may be available. Please call the Microbiology Dept at 239-436-6591.